Mal de Meleda: Diagnostic Work-up and Therapy with Low-dose Acitretin

Isabella POSPISCHIL, Klaus ENZELSBERGER, Susanne GROSS, Wolfram HOETZENECKER and Tobias W. FISCHER*
Department of Dermatology, Kepler University Hospital, Johannes Kepler University, AT-4021 Linz, Austria. *E-mail: Tobias.Fischer@keplerunllinikum.at
Accepted May 4, 2022; Epub ahead of print May 4, 2022
Acta Derm Venereol 2022; 102: adv00758. DOI: 10.2340/actadv.v102.995

Keratodermia palmoplantaris transgrediens et progrediens is a rare autosomal recessive hyperkeratotic skin disorder (estimated prevalence 1/100,000), first described in 1826 by Luko Stulli as “Mal de Meleda” on the Adriatic island of Mijet (Meleda) in Southern Croatia (1). It belongs to the heterogeneous group of hereditary palmoplantar keratodermas (PPKs) which can be focal or diffuse with or without extracutaneous manifestations (i.e. syndromic) and variable prognosis. An exact diagnosis followed by genetic counselling is important for the patient and affected family. However, given the diversity of hereditary PPKs and their rareness, making the correct diagnosis and choice of optimal therapy might be challenging.

CASE REPORT

An 82-year-old Caucasian male presented with a history of palmoplantar hyperkeratosis since early childhood with extension to the dorsal aspects of the feet and hands and progression with age. He had a history of type 2 diabetes, arterial hypertension, chronic kidney disease and age-related macular degeneration. His ancestry search back to the year 1700 and his 5 own children (4 sons, 1 daughter) did not reveal a PPK or other dermatological diseases.

Clinical examination revealed plaque-like yellowish and waxy palmoplantar hyperkeratosis with adjacent sharply demarcated, fine scaly erythema, which extended to the forearms and lower legs in a cuff-like (gloves and socks) distribution (Fig. 1a–d). In addition, nail dystrophy (Fig. 1e) and malodour was found. Total-body skin examination, including oral cavity, teeth and scalp hair, revealed no pathological findings. A punch biopsy from plantar skin revealed hyperkeratosis, mild hypergranulosis and a discrete perivascular inflammatory infiltrate in the superficial dermis, but no epidermolysis. Fungal culture from palmoplantar skin revealed *Trichophyton verrucosum*.

Based on the early onset of disease, clinical presentation with palmoplantar transgredient and progressive hyperkeratosis and likely autosomal recessive inheritance, a hereditary PPK, specifically keratosis palmoplantaris transgrediens et progrediens (Mal de Meleda) was suspected. This clinical diagnosis was later confirmed by detecting a homozygous *SLURP-1* gene mutation.

The patient received intensive topical treatment, including keratolytic agents, tretinoin and class III steroids. In addition, he carefully removed hyperkeratotic skin after a daily hand and foot bath, sometimes with support of a skin fraze. The *Trichophyton* superinfection was treated with topical econazole and systemic terbinafine (250 mg/day for 4 weeks).

As acitretin is generally reported to be beneficial for hereditary PPKs and their rareness, making the correct diagnosis and choice of optimal therapy might be challenging.

As differential diagnosis, a PPK Unna-Thost-Vörner (epidermolytic, non-transgredient) or the transgredient and progressive PPK Grether were excluded due to clinical manifestation and mode of inheritance (dominant); thus, an autosomal recessive transgredient and progressive isolated PPK, such as PPK type Nagashima or Mal de Meleda, was likely (5). Since the Nagashima type is present only in Asians, keratosis palmoplantaris transgrediens et progrediens (Mal de Meleda) remained the final suspected clinical diagnosis in the current patient.

As in this case, Mal de Meleda manifests soon after birth with diffuse transgredient palmoplantar hyperkeratosis and erythema that progresses with age (progrediens). Furthermore, hyperkeratotic plaques on elbows and
knees, nail dystrophy, perioral erythema, angular cheilitis, digit tapering, hyperhidrosis, microbial superinfections and malodour can be present. Rarely, pseudoainhum and melanoma can occur in affected areas (6, 7). In contrast to other hereditary PPKs, epidermolysis is lacking (5). The first 3 causative mutations were identified in 2001 in the secreted mammalian Ly-6/6uPAR-related protein 1 (SLURP-1) gene of which one is a single nucleotide deletion (c82delT) that was also detected in the current patient (8). To date, at least 20 different mutations in the SLURP-1 gene are known to cause Mal de Meleda, and, among others, a novel missense mutation was detected in a 27-year-old Austrian patient of Turkish origin in 2011 (9). SLURP-1 is a regulator of epidermal homeostasis, and its mutation impairs keratinocyte differentiation due to decreased transglutaminase 1, keratin 10, p21 and caspase 3, leading to hyperparakeratosis (10). Furthermore, SLURP-1 controls inflammatory cytokines, such as tumour necrosis factor (TNF)-α, interleukin (IL)-1 or IL-6 (11, 12).

The therapeutic management of hereditary PPKs, recently reviewed by Bodemer et al. (13), aims at symptom relief, as a curative approach is currently not available. While international therapeutic guidelines are lacking due to the rareness of the disease, common approaches include topical keratolytic, anti-inflammatory and skin care agents, regular mechanical debridement and consequent therapy of bacterial/fungal superinfections (13). Systemic therapy includes oral retinoids, although worsening, especially in epidermolytic PPKs, may occur.

Isotretinoin, acitretin and altitretinoin in doses between 20 and 50 mg/day have been reported efficient after 3–4 months of therapy in PKKs including Mal de Meleda (2, 14, 15); however, with blistering, dryness and skin tenderness or severe diffuse hair loss as side-effects. A retrospective study in 30 patients with another plantar keratoderma (pachyonychia congenita) by Gruber et al. (4) revealed low-dose (< 25 mg/day) acitretin for a longer duration (> 5 months) being more beneficial than higher doses (> 25 mg/day) for a shorter time (≤ 5 months) and more efficient than isotretinoin. Our observation is in agreement with a successful treatment of a less severe PPK (punctate PPK type 1) with low-dose acitretin (10 mg/day) (3). Thus, low-dose (i.e. 10 mg/day) acitretin therapy combined with consequent topical treatment represents an efficient and well tolerated long-term therapeutic approach for Mal de Meleda.

The authors have no conflicts of interest to declare.

REFERENCES

1. Fatovic-Ferencic S, Holubar K. The portrait and paper of a forgotten hero – Luca Stulli (1772–1828) and the Mal de Meleda of yesteryear: a 175-year anniversary. J Invest Dermatol 2001; 116: 198–199.
2. van de Kerkhof PC, van Dooren-Greebe RJ, Steijlen PM. Acitretin in the treatment of mal de Meleda. Br J Dermatol 1992; 127: 191–192.
3. Jo JW, Jeong DS, Kim CY. Case of punctate palmoplantar keratoderma type I treated with combination of low-dose oral acitretin and topical salicylic acid and steroid. J Dermatol 2018; 45: 609–612.
4. Gruber R, Edlinger M, Kaspar RL, Hansen CD, Leachman S, Milstone LM et al.. An appraisal of oral retinoids in the treatment of pachyonychia congenita. J Am Acad Dermatol 2012; 66: e193–e199.

5. Guerra L, Castori M, Didona B, Castiglia D, Zambruno G. Hereditary palmoplantar keratodermas. Part I. Non-syndromic palmoplantar keratodermas: classification, clinical and genetic features. J Eur Acad Dermatol Venereol 2018; 32: 704–719.

6. Lestringant GG, Hadi SM, Qayed KI, Blayney B. Mal de Meleda: recessive transgressive palmoplantar keratoderma with three unusual facultative features. Dermatology 1992; 184: 78–82.

7. Mozzillo N, Nunziata CA, Caraco C, Fazioi F, Botti G, Melanoma Cooperative Group. Malignant melanoma developing in an area of hereditary palmoplantar keratoderma (Mal de Meleda). J Surg Oncol 2003; 84: 229–233.

8. Fischer J, Bouadjar B, Heilig R, Huber M, Lefèvre C, Jobard F et al. Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum Mol Genet 2001; 10: 875–880.

9. Gruber R, Hennies HC, Romani N, Schmuth M. A novel homozygous missense mutation in SLURP1 causing Mal de Meleda with an atypical phenotype. Arch Dermatol 2011; 147: 748–750.

10. Arredondo J, Chernyavsky AI, Webber RJ, Grando SA. Biological effects of SLURP-1 on human keratinocytes. J Invest Dermatol 2005; 125: 1236–1241.

11. Chernyavsky AI, Galitovsky V, Shchepotin IB, Grando SA. Anti-inflammatory effects of the nicotinergic peptides SLURP-1 and SLURP-2 on human intestinal epithelial cells and immunocytes. Biomed Res Int 2014; 2014: 609086.

12. Kudo M, Ishiura N, Tamura-Nakano M, Shimizu T, Kamata M, Akasaka E et al.. Abnormal keratinization and cutaneous inflammation in Mal de Meleda. J Dermatol 2020; 47: 554–558.

13. Bodemer C, Steijlen P, Hautier JM, O’Toole EA. Treatment of hereditary palmoplantar keratodermas: a review by analysis of the literature. Br J Dermatol 2020; 184: 393–400.

14. Bergfeld WF, Derbes VJ, Elias PM, Frost P, Greer KE, Shupack JL. The treatment of keratosis palmaris et plantaris with isotretinoin: a multicenter study. J Am Acad Dermatol 1982; 6: 727–731.

15. Park HK, Kim EJ, Ko JY. Alitretinoin: treatment for refractory palmoplantar keratoderma. Br J Dermatol 2016; 174: 1143–1144.